

1 **Supplemental Material**

2 **A Simplified Derivative of Human Defensin 5 with Potent Efficiency against**
3 **Multidrug-resistant *Acinetobacter baumannii***

4 Cheng Wang,^a Gaomei Zhao,^a Song Wang,^a Yin Chen,^a Yali Gong,^b Shilei Chen,^a Yang

5 Xu,^a Mengjia Hu,^a Xinmiao Wang,^a Hao Zeng,^a Aiping Wang,^a Dengqun Liu,^a

6 Yongping Su,^a Tianmin Cheng,^a Fang Chen,^{a#} and Junping Wang^{a#}

7 State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Combined
8 Injury of PLA, Chongqing Engineering Research Center for Nanomedicine, College of
9 Preventive Medicine, Third Military Medical University^a; Institute of Burn Research,
10 Southwest Hospital, Third Military Medical University^b

11 [#]Corresponding authors

12
13 **CONTENTS:**

14 **TABLE S1** Sequence, purity, and mass of the peptides (P3)

15 **FIG S1** Cytotoxic evaluation of HD5, HD5d5, and CIP to erythrocytes and human
16 epithelial HaCaT cells (P4-5)

17 **FIG S2** Scanning electron microscopy (SEM) observing the morphological changes of
18 MDRAb exposed to HD5 and HD5d5 (P6)

19 **FIG S3** HD5d5 elicits agglutination of the cytoplasmic content of MDRAb (P7)

20 **FIG S4** HD5d5 neutralizes AbOmpA in a dose-dependent manner (P8)

21 **FIG S5** MHB lowers the antibacterial activity of HD5 in a dose-dependent manner (P9)

22 **FIG S6** Amino acid sequences of human α - and β -defensins (P10)

23 **FIG S7**API 20NE and 16S rDNA sequencing confirming microbial species (P11)

24 **FIG S8** Kirby-Bauer method determining the antibiotic resistance of isolated *A.*

25 *baumannii* (P12)

26 **FIG S9** Information on the pET-30a-OmpA expression plasmid (P13)

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42 **TABLE S1** Sequence, purity, and mass of the peptides

Peptide	Sequence	Purity ^a	k' ^a	Theoretical mass ^b	Measured mass ^c
HD5	ATCYCRTGRCATRESLSGVCEISGRLYRLCCR	96.0%	3.96	3582.2	3582.3
FITC-HD5	FITC- ATCYCRTGRCATRESLSGVCEISGRLYRLCCR	96.7%	3.83	4090.8	4090.2
HD5d1	ATAYARTGRAATRESLSGVAEISGRLYRLAAR	98.4%	4.34	3395.8	3395.5
HD5d2	ATCYARTGRAATRESLSGVAEISGRLYRLACR	95.4%	4.26	3458.0	3458.4
HD5d3	ATAYCRTGRAATRESLSGVCEISGRLYRLAAR	96.6%	4.68	3458.0	3458.0
HD5d4	ATAYARTGRCATRESLSGVAEISGRLYRLCAR	95.6%	4.27	3458.0	3458.2
HD5d5	ARARCRRGRAARRRRLRGVCRIRGRLRLAAR	97.1%	3.78	3870.7	3870.9
HD5d6	AKAKCRKGRAAKRKCLKGVCRIRGRLKRLAAR	96.8%	3.85	3618.6	3618.7
FITC-HD5d5	FITC-ARARCRRGRAARRRRLRGVCRIRGRLRLAAR	96.9%	3.67	4379.3	4379.6

43 ^a Measured by reverse-phase high-performance liquid chromatography (HPLC). Data were
 44 obtained at 25 °C on a Phenomenex/Luna C18 (2) column (5 µm, 4.6 × 150 mm) applying a linear
 45 gradient of 20-40% buffer B [buffer A: 0.1% trifluoroacetic acid in water; buffer B: 0.09%
 46 trifluoroacetic acid in (80% acetonitrile plus 20% water)] at a flow rate of 1 ml/min over 20 min. k',
 47 capacity factor, calculated as the retention time of peptides in stationary phase divided by the
 48 retention time of the solvent.

49 ^b Calculated on <http://web.expasy.org/protparam/>.

50 ^c Measured by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF, SHIMADZU,
 51 Kyoto, JPN).

52

53

54

55

56

57 **FIG S1** Cytotoxic evaluation of HD5, HD5d5, and CIP to erythrocytes and human
58 epithelial HaCaT cells. (A) Hemolytic experiment. Mouse blood was collected and
59 washed with cold PBS, which was then diluted 1:5. The suspension was incubated with
60 peptides at 37 °C for 15 min. The percentage of hemolysis was determined as $(A_{\text{pep}} -$
61 $A_{\text{blank}}) / (A_{\text{tot}} - A_{\text{blank}}) \times 100\%$. The total hemolysis (A_{tot}) was actualized by 1% Triton
62 X-100. HD5, HD5d5, and CIP were harmless to erythrocytes, manifested by a hemolysis
63 less than 1%. The results derived from three independent experiments conducted in
64 duplicate are presented as means \pm SD. (B) Human epithelial HaCaT cells (CAS,
65 Shanghai, CHN) were cultured in 1640 medium (SH30809.01B, HyClone) and seeded in
66 96-well plates at a density of 4000 CFU/well. After adherence, cells were washed with
67 PBS and co-incubated with 50, 100, and 150 $\mu\text{g/ml}$ peptides at 37 °C for 24 h. CCK-8
68 method was used to detect cell survival. The survival rate was calculated as $(A_{\text{pep}} / A_{\text{blank}})$
69 $\times 100\%$. This experiment was conducted in duplicate and repeated three times. Results
70 are presented as means \pm SD. *, $p < 0.05$, compared to the survival of cells exposed to 50
71 $\mu\text{g/ml}$ HD5.

72 Note: The figure is shown in next page.

73

74


75

76

77

78 **FIG S1** Cytotoxic evaluation of HD5, HD5d5, and CIP to erythrocytes and human
79 epithelial HaCaT cells.

80



81

82

83

84

85


86

87

88

89 **FIG S2** Scanning electron microscopy (SEM) observing the morphological changes of
90 *MDRab* exposed to HD5 and HD5d5. *MDRab* cells (1×10^8 CFU, 50 μ l) cultured to
91 mid-logarithmic phase were co-incubated with 5 μ l of peptides (1mg/ml) at 37 $^{\circ}$ C for 30
92 min. Bacteria were coated a coverslip and dried at room temperature. Samples were fixed
93 with 2.5% glutaraldehyde at 4 $^{\circ}$ C, dehydrated with gradient concentrations of ethanol,
94 and desiccated using tert-butyl alcohol. A gold coating was used to prevent the
95 accumulation of static electric fields in the specimen. The extra high tension of SEM is
96 2,000 V. Arrow-pointed cells generally maintained the integrity, indicating that these cells
97 are freed from catastrophic collapse. C.C, catastrophic collapse.

98



100

101

102

103

104

105

106 **FIG S3** HD5d5 elicits agglutination of the cytoplasmic content of MDR*Ab*. Bacteria
107 cultured to stationary phase were centrifuged and resuspended in 200 μ l of 10 mM
108 sodium phosphate (pH 7.4). Cytoplasmic content was obtained and diluted to 1500 μ g/ml.
109 A 10 μ l aliquot of the content was co-incubated with 100 and 500 μ g/ml peptides at room
110 temperature, and 10 μ l of the mixture was placed on a glass slide. Based on the changes
111 of the liquid turbidity, we proposed that HD5d5 was stronger than HD5 to cause
112 agglutination of the cytoplasmic content.

113



115

116

117

118

119

120

121

122


123

124

125

126 **FIG S4** HD5d5 neutralizes *AbOmpA* in a dose-dependent manner. Human laryngeal
127 epithelial HEp-2 cells were cultured in DMEM supplemented with 10% foetal bovine
128 serum at 37 °C. Cells were seeded into a 96-well plate at a density of 5000 CFU/well.
129 After adherence, cells were washed with PBS and co-incubated with 5 µg/ml *AbOmpA* in
130 the absence or presence of peptides at 37 °C for 9 h. Peptides were prepared in sterile
131 water at concentrations of 10, 30, and 50 µg/ml. Before co-incubation, peptides and
132 *AbOmpA* were mixed at 37 °C for 10 min. Absorbance was determined at 450 nm using a
133 microplate reader. Results derived from three independent experiments conducted in
134 duplicate are presented as means ± SD. n.s, not significantly; **, p < 0.01, compared to
135 the absorbance of the *AbOmpA* group.

136



137

138


139

140

141

142 **FIG S5** MHB lowers the antibacterial activity of HD5 in a dose-dependent manner. The
143 virtual colony count assay was employed to determine the bactericidal potency of HD5
144 against MDRAb in 10 mM sodium phosphate buffer (pH 7.4) containing 1%, 5%, 10%,
145 20%, and 40% MHB. HD5 was prepared in sterile water at concentrations of 12.5 and
146 6.25 µg/ml. Results derived from three independent experiments conducted in duplicate
147 are shown as means ± SD. n.s, not significantly; **, p < 0.01, compared to the bacterial
148 killing of 12.5 µg/ml HD5. ##, p < 0.01, compared to the bacterial killing of 6.25 µg/ml
149 HD5.

150



151

152

153

154

155

156

157 **FIG S6** Amino acid sequences of human α - and β -defensins. Cysteines are colored red
 158 and box-linked based on the disulfide connectivity. Cys1-6, Cys2-4, and Cys3-5 pairing is
 159 highlighted in green, blue, and orange, respectively.
 160

Human α -defensins

HNP 1	AC	YC	RI	PAC	I	AG	ERRY	GT	C	I	YQ	RL	WA	F	CC																	
HNP 2		C	Y	C	R	I	P	A	C	I		A	G	E	R	R	Y	G	T	C	I		Y	Q	G	R	L	W	A	F	C	C
HNP 3	D	C	Y	C	R	I	P	A	C	I		A	G	E	R	R	Y	G	T	C	I		Y	Q	G	R	L	W	A	F	C	C
HNP 4	V	C	S	C	R	L	V	F	C	R	R	T	E	L	R	V	G	N	C	L	I	G	G	V	S	F	T	C	C	T	R	V
HD 5	A	T	C	Y	C	R	T	G	R	C	A	T	R	E	S	L	S	G	V	C	E	I	S	G	R	L	Y	R	L	C	C	R
HD 6	A	F	T	C	H	C	R	R	S	C	Y	S	T	E	Y	S	Y	G	T	C	T	V	M	G	I	N	H	R	F	C	C	L


Human β -defensins

HBD 1	D	H	N	C	V	S	S	G	G	Q	C	L	Y	S	A	C	P	I	F	T	K	I	Q	G	T	C	Y	R	G	K	A	C	C	K							
HBD 2	G	I	G	D	P	V	T	C	L	K	S	G	A	I	C	H	P	V	F	C	P	R	R	Y	K	Q	I	G	T	C	G	L	P	G	T	C	C	K	K	P	
HBD 3	G	I	I	N	L	Q	K	Y	C	R	V	R	G	G	R	C	A	V	L	S	C	L	P	K	E	E	Q	I	G	K	C	S	T	R	G	R	C	C	R	R	K
HBD 4	Q	S	I	N	N	P	I	T	C	L	T	K	G	G	V	C	W	G	P	C	T	G	G	F	R	Q	I	G	T	C	G	L	P	R	V	R	C	C	K	K	

161
 162
 163
 164
 165
 166
 167
 168
 169
 170

171 **FIG S7** API 20NE and 16S rDNA sequencing confirming microbial species. (A) The
 172 isolated strain was cultured in MHB and analysed by API 20NE (Bio-Mérieux, Marcy
 173 l'Etoile, France), obtaining a code of 0040437, which is indicative of the being of *A.*
 174 *baumannii*. (B) Bacterial genomic DNA was extracted and sequenced by Beijing
 175 Genomics Institute. The data was analysed by the Basic Local Alignment Search Tool
 176 (BLAST) of NCBI, demonstrating that the isolate is *A. baumannii*.

177



178

179

180


181

182

183

184 **FIG S8** Kirby-Bauer method determining the antibiotic resistance of isolated *A.*
185 *baumannii*. Isolated *A. baumannii* cultured overnight was coated on the MHB plate,
186 which was then dried at room temperature. Six OXOID antibiotic tablets, specifically,
187 TET, AMK, CTX, CIP, ATM, and SXT, were subsequently attached. Bacteria were
188 incubated at 37 °C for 16 h. The multi-drug resistance was confirmed by the Clinical and
189 Laboratory Standards Institute (CLSI) antimicrobial susceptibility testing standards.

190



191

192

193

194

195

196



197

198 **FIG S9** Information on the pET-30a-OmpA expression plasmid. (A) The sequence of the
 199 optimized gene encoding *AbOmpA*, which was inserted into a pET30a vector through
 200 NdeI and HindIII. (B) Schematic diagram of the pET-30a-OmpA expression plasmid. (C)
 201 SDS-PAGE and Coomassie blue staining analyzing the purified efficiency of *AbOmpA*.
 202 M, marker; 1, lysed supernatant dissolved in 8 M urea solution; 2, lysed supernatant
 203 purified by Ni-IDA resin; 3-14, purified product eluted by different concentrations of
 204 imidazole.

A

```

NdeI
CatATGCACCATCACCATCACCAT
1   CAGGATAGTC AGCACAACAA CGGCGGTAAA GACGGTAATC TGACCAACGG TCCGGAAC TG
61  CAGGATGACC TGTTTGTGG  CGCAGCACTG GGTATTGAAC TGACCCCGTG GCTGGGTTTT
121 GAAGCGGAAT ACAACCAGGT TAAAGGCGAC GTTGATGGCG CAAGCGCAGG CGCAGAATAT
181 AAACAGAAAC AGATCAACGG CAACTTCTAC GTCACCAGCG ACCTGATCAC CAAAACTAC
241 GACAGCAAAA TCAAACCGTA CGTTCTGCTG GCGCGGGGTC ATTACAAATA CGATTTTCGAC
301 GGTGTTAATC GCGGTACCCG CGGTACCTCT GAAGAAGGTA CGCTGGGTAA CGCAGGGGTT
361 GGCGCATTTF GGCGTCTGAA CGACGCACTG AGTCTGCGTA CCGAAGCAGC CGCAACCTAT
421 AACGCGGACG AAGAGTTCTG GAACTATAACC GCACTGGCAG GTCTGAAACG TGTCTGGGGT
481 GGTCATCTGA AACCGGCTGC ACCGGTTGTT GAAGTTGCAC CGGTTGAACC GACCCCGGTT
541 GCACCGCAAC CGCAAGAACT GACCGAAGAT CTGAACATGG AACTGCGCGT CTTCTTCGAC
601 ACCAACA AAA GCAACATCAA AGACCAGTAC AAACCGGAGA TCGCGAAAGT TCGCGGAGAAA
661 CTGAGCGAAT ATCCGAACGC AACCGCACGT ATTGAAGGTC ATACCGATAA CACCGGTCCG
721 CGTAAACTGA ACGAACGCTC GTCTCTGGCA CGTGCAATA GCGTTAAAAG CGCGCTGGTT
781 AACGAATATA ACGTCGACGC AAGCCGCTCG TCTACCCAAG GTTTGTCTTG GGATCAGCCG
841 ATTGCGGACA ACAAACCAA AGAAGGCCGC GCAATGAACC GTCGCGTTTT TGCAGCCATT
901 ACCGGTTCTC GTACCGTTGT TGTTC AACCG GGTCAAGAAG CAGCAGCACC GGCAGCAGCA
961 CAA
TAATGA AAGCTT
HindIII
  
```



205